Prescription opioid exposure falls as treatment medication reach expands
HHS and ASPE analyses show lower prescription opioid dispensing and more patients filling two treatment medications, while leaving mortality causes unresolved.
Event / data period:
Published: · Updated:

The U.S. Department of Health and Human Services published new analyses on October 27 describing a decade of change in prescription opioid exposure and pharmacy fills for two medications used in substance-use-disorder treatment. The underlying series, prepared by the Office of the Assistant Secretary for Planning and Evaluation, compares population-adjusted dispensing measures with their March 2015 levels through March 2026. In the latest period, opioid prescription fills stood at 45.3 percent of that baseline, total opioid dosage at 35.2 percent, and retail-pharmacy patients receiving opioid prescriptions at 49.6 percent. The number of patients filling prescriptions for buprenorphine or naltrexone was 218 percent of its baseline.
The measures describe distinct parts of a changing treatment landscape. The analysis uses three-month moving averages per 100,000 population and indexes each series to March 2015 = 100. Prescription counts and dosage include retail and mail channels, while the patient count for opioid prescriptions is based on retail dispensing. For buprenorphine and naltrexone, prescription measures include retail and mail but patient counts identify people with retail fills; the study excludes two buprenorphine formulations commonly used for pain. Thus the 218 percent figure is not a count of all people receiving treatment for opioid use disorder, and the analysis does not include methadone dispensed through certified opioid treatment programs.
The authors report that total morphine milligram equivalents, a standardized dosage measure that adjusts for different opioid drugs and strengths, declined more than prescription counts. They say that pattern is consistent with lower average dosage exposure as well as fewer prescription transactions. The patient-count measure also fell, indicating fewer people received prescription opioids through the measured retail channel. On the treatment side, patient counts for buprenorphine or naltrexone rose more than prescription counts: by March 2026, patient fills were 218 percent of baseline and prescriptions were 148.1 percent. The analysis suggests longer days supplied per prescription may help explain the divergence. These measures show pharmacy dispensing, not whether each person began or remained in clinical treatment.
Mortality context does not establish what caused the changes. The linked Health Affairs analysis explains that overdose estimates are provisional and may involve multiple drugs. It also describes how the illicit market shifted toward fentanyl, which can be more potent and easier to obtain than prescription opioids. In that setting, reducing prescription exposure is a prevention measure, but it is not by itself a sufficient explanation for mortality trends; substitution toward illicit drugs can alter risk in complex ways.
HHS’s announcement attributes the progress to policies across administrations, including prescribing changes, fentanyl enforcement and treatment programs, and highlights the 2025 SUPPORT Act reauthorization and a 2026 federal recovery initiative. The analyses document trends but do not isolate the effect of any one law or administration. They rely on population-adjusted IQVIA pharmacy data and identify limitations in channel coverage and treatment definitions. The authors emphasize that prescription counts alone can miss dosage and patient changes, while legal authority for treatment does not guarantee practical access to diagnosis, medication, follow-up and support. The results support cautious monitoring across multiple measures; they do not show that all opioid-related deaths have reached a decade low or that the same trend holds for every community.
Data
Opioid dispensing and treatment indicators
Prescription and treatment-medication dispensing measures indexed to March 2015.
- Opioid prescriptions relative to baseline
- 45.3 percent
- 2026-03 · Observed
- Total opioid dosage relative to baseline
- 35.2 percent
- 2026-03 · Observed
- Retail patients receiving opioid prescriptions relative to baseline
- 49.6 percent
- 2026-03 · Observed
- Patients filling buprenorphine or naltrexone relative to baseline
- 218 percent
- 2026-03 · Observed
Methodology
Pharmacy measures use population-adjusted three-month moving averages indexed to March 2015=100; values are the source-reported index levels.
Updated:
Subjects and places
Subject proposals
- HealthSuggested
- Preserved editorial category/topic; broad candidate onlywww.hhs.gov ↗www.healthaffairs.org ↗
Geographic references
Only source-provided geographic references are shown. Opening an external map is optional. Optional story maps use OpenStreetMap. Opening a map sends your IP address and this site’s address to the map provider; location data remains readable as text without loading the map.
- United States · Place role: Coverage · Place type: Country or area · Location precision: RegionalEvidence
- Explicit preserved editorial country/region; no city or national centroid inferredwww.hhs.gov ↗www.healthaffairs.org ↗